Business
GE HealthCare Announces FES PET Imaging Recommendation in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
NCCN Guidelines® for clinicians and patients now recommend the use of FES PET for ER+ positive disease under certain circumstances during the systemic
About this update from Ge Healthcare Technologies Inc.
[{"type":"text","content":"\n\nNCCN Guidelines® for clinicians and patients now recommend the use of FES PET for ER+ positive disease under certain circumstances during the systemic staging workup of patients with recurrent or metastatic breast cancer (MBC).\n\n\n\n\nCerianna (fluoroestradiol F18) injection is the first and only U.S. Food and Drug Administration (FDA) approved imaging agent helping clinicians assess estrogen receptor-positive (ER+) lesion status to potentially aid in better informing clinical decisions and improving patient outcomes.\n\n\n\nIn March 2023, Appropriate Use Criteria (AUC) for ER-targeted PET imaging was also published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI)1.\n\n\n\n MARLBOROUGH, Mass.--(BUSINESS WIRE)--\nGE HealthCare, a leader in breast cancer care technology and diagnostics, has today announced that NCCN Guidelines® for clinicians and patients now recommend the use of FES PET for ER+ positive disease under certain circumstances during the systemic staging workup of patients with recurrent or metastatic breast cancer. GE HealthCare’s Cerianna, available in the U.S., is the only FDA approved FES PET imaging agent. This inclusion in the NCCN Guidelines comes after the Society of Nuclear Medicine and Molecular Imaging (SNMMI) recently published Appropriate Use Criteria to guide referring and imaging physicians in appropriate use of estrogen receptor (ER)-targeted PET imaging with 16α-18F-fluoro-17ß Fluoroestradiol.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230524005415/en/FES PET is now included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) (Graphic: Business Wire)\nIn the U.S., it is estimated that 181,0002 people have metastatic breast cancer (also called stage 4)3, with a five-year survival rate of 28 percent4. Currently, when treating metastatic breast cancer patients, oncologists base clinical decisions on diagnostic tools including biopsy results which only represent the sampled area of the tumor. However, ER expression – one of the most common breast cancer biomarkers - can vary both within the primary tumor, across different lesions5, and change over time.\n\n\nCerianna is indicated for use with PET imaging for the detection of ER+ lesions as an adjunct to biopsy in patients with recurrent or metast...